JP4782854B2 - 癌患者の潜在的転移能、予後、又は全生存を予測する方法 - Google Patents
癌患者の潜在的転移能、予後、又は全生存を予測する方法 Download PDFInfo
- Publication number
- JP4782854B2 JP4782854B2 JP2009056356A JP2009056356A JP4782854B2 JP 4782854 B2 JP4782854 B2 JP 4782854B2 JP 2009056356 A JP2009056356 A JP 2009056356A JP 2009056356 A JP2009056356 A JP 2009056356A JP 4782854 B2 JP4782854 B2 JP 4782854B2
- Authority
- JP
- Japan
- Prior art keywords
- hif
- snail
- twist
- cancer
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
頭頸部扁平上皮癌(HNSCC)に対する診断マーカーセット
2001年1月から2004年12月の間に台北マッケイ記念病院(Taipei Mackay Memorial Hospital)と台北退役軍人総合病院(Taipei Veterans General Hospital)で治療を受けたHNSCC患者147名を遡及的に解析した。本研究は台北退役軍人総合病院(Taipei Veterans General Hospital)機関審査委員会により承認された。HNSCC患者147名の臨床特性を表1に示す。
略称:OS, 全生存;RFS, 無再発性生存;* 生存中央値に達しなかった。
サンプル処理とIHC手順は記載のように実施した(非特許文献38)。HIF -1α、CA IX、Snail、及びTWISTのIHCの結果の解釈は、以前に記載の基準に従い病理学者2名により別々に行った(非特許文献15、18、22、34、35、38)。
HIF -1α、TWIST、及び Snailの免疫反応性を、核質発現に従い0から3+に評点し(0, 染色されず;1+, 1-25% 核質タンパクの染色; 2+, 26-50% 核質タンパクの染色; 3+, >50% 核質タンパクの染色)、3+ (>50% 核質タンパクの染色)のみがIHCで陽性な結果と考えた(非特許文献14、18、22、34、35、38)。
独立のスチューデントt検定を用いて二群間の連続変数を比較し、χ2検定を二値変数の比較に適応した。カプラン−マイヤー(Kaplan-Meier)の評価を転移なしで且つ全生存の解析に用い、ログランク検定を用いてその差を比較した。コックス(Cox)の比例ハザードモデルを多変量生存率分析に適応し、独立の予後因子を試験した。統計解析の全ての対照群は、図の凡例に別に規定しない限りは通常パネルの第一群である。統計的有意性のレベルは全試験で0.05に設定した。
非小細胞肺癌(NSCLC)用の予測マーカーセット
2003年1月から2004年12月の間に台北マッケイ記念病院(Taipei Mackay Memorial Hospital)と台北退役軍人総合病院(Taipei Veterans General Hospital)で外科的切除を受けたNSCLC 患者87名を遡及的に解析した。本研究は台北退役軍人総合病院(Taipei Veterans General Hospital)機関審査委員会により承認された。NSCLC 患者87名の臨床特性を表3に示す。
* 生存の中央値に達しなかった。
実施形態1と同様の手順で実施した。HIF -1α、TWIST、及び Snailの免疫反応性を0から3+に評点し(0, 染色されず;1+, 1-25% 核質タンパクの染色; 2+, 26-50% 核質タンパクの染色; 3+, >50% 核質タンパクの染色)、3+ (>50% 核質タンパクの染色)のみがIHCで陽性な結果と考えた。全マーカーのIHC染色の代表例を図7に示す。
ここで実施形態1に対するのと同一の統計法を用いた。図8(a)〜(c)に示した生存率分析において、NSCLC のHIF -1α、TWIST、及び Snailの各過剰発現はより短期の全生存と関連した。更にNSCLC におけるHIF -1α、TWIST、及び Snailのマーカーの内の任意の2種の同時発現パターンの予後の有意性を調べるために、NSCLC 症例のサブグループ分析を図9〜(c)に示した。図10(a)から、HIF -1α、TWIST、及び Snailの過剰発現の任意の2種(グループ3)、及びHIF -1α(+)/TWIST(+)/Snail(+)(グループ4)は、他のグループに比べより短期の全生存を有した。更に図10(b)から、HIF -1α、TWIST、及び Snailの任意の二種又は全ての同時発現(グループ2)は、より悪い全生存を有意に有した。従って図10の結果に基づき、HIF -1α、TWIST、及び Snailの内の任意の二種又は三種のマーカーの同時発現は、発現なし又はマーカー一種の発現より悪い予後及び全生存を有した。
Claims (2)
- 非小細胞肺癌(NSCLC)患者の予後又は全生存を予測する方法で、その方法が
前記非小細胞肺癌(NSCLC)患者から得られた生体サンプルについて、
HIF-1α、TWIST、及び Snailからなる一群から選択した少なくとも二種の診断マーカーが前記生体サンプルで同時発現するか否かを測定することからなり、
ここで前記生体サンプル中の前記診断マーカーの同時発現は、前記ガン患者の予後又は全生存に対する指標である方法。 - 前記診断マーカーがHIF-1α、TWIST、及び Snailを含む請求項1に記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009056356A JP4782854B2 (ja) | 2009-03-10 | 2009-03-10 | 癌患者の潜在的転移能、予後、又は全生存を予測する方法 |
EP09075122A EP2228655A1 (en) | 2009-03-10 | 2009-03-18 | Method of predicting metastatic potential, poor prognosis or lower overall survival of cancer patients |
TW99106026A TWI384219B (zh) | 2009-03-10 | 2010-03-02 | 預測癌症病患之癌細胞轉移、預後或整體存活率的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009056356A JP4782854B2 (ja) | 2009-03-10 | 2009-03-10 | 癌患者の潜在的転移能、予後、又は全生存を予測する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010210393A JP2010210393A (ja) | 2010-09-24 |
JP4782854B2 true JP4782854B2 (ja) | 2011-09-28 |
Family
ID=40742869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009056356A Expired - Fee Related JP4782854B2 (ja) | 2009-03-10 | 2009-03-10 | 癌患者の潜在的転移能、予後、又は全生存を予測する方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2228655A1 (ja) |
JP (1) | JP4782854B2 (ja) |
TW (1) | TWI384219B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010204741B2 (en) | 2009-01-14 | 2016-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ratio based biomarkers and methods of use thereof |
JP2014516531A (ja) * | 2011-05-25 | 2014-07-17 | ノバルティス アーゲー | 肺癌に対するバイオマーカー |
EP2972374A2 (en) * | 2013-03-15 | 2016-01-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ratio based biomarkers and methods of use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1679379A1 (en) * | 2005-01-06 | 2006-07-12 | UMC Utrecht Holding B.V. | Diagnosis of metastases in HNSCC tumours |
CA2689714A1 (en) * | 2007-06-01 | 2008-12-04 | Agendia B.V. | Prognostic gene expression signature for non small cell lung cancer patients |
WO2009009739A2 (en) * | 2007-07-12 | 2009-01-15 | Theracrine, Inc. | Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
-
2009
- 2009-03-10 JP JP2009056356A patent/JP4782854B2/ja not_active Expired - Fee Related
- 2009-03-18 EP EP09075122A patent/EP2228655A1/en not_active Withdrawn
-
2010
- 2010-03-02 TW TW99106026A patent/TWI384219B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201033613A (en) | 2010-09-16 |
EP2228655A1 (en) | 2010-09-15 |
TWI384219B (zh) | 2013-02-01 |
JP2010210393A (ja) | 2010-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yun et al. | Loss of E-Cadherin expression is associated with a poor prognosis in stage III colorectal cancer | |
Bronsert et al. | Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer | |
Zhao et al. | Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer | |
Scheble et al. | ERG rearrangement in small cell prostatic and lung cancer | |
Yoshida et al. | Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas | |
Shoji et al. | The preoperative controlling nutritional status score predicts survival after curative surgery in patients with pathological stage I non-small cell lung cancer | |
Zhao et al. | Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma | |
Zamanian–Azodi et al. | Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach | |
Zhou et al. | Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials | |
He et al. | Circulating tumor cells as a biomarker to assist molecular diagnosis for early stage non-small cell lung cancer | |
Xu et al. | Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy | |
Jurmeister et al. | Immunohistochemical analysis of Bcl‐2, nuclear S100A4, MITF and Ki67 for risk stratification of early‐stage melanoma–A combined IHC score for melanoma risk stratification | |
da Costa et al. | Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma | |
Büscheck et al. | Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma | |
Sheta et al. | Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer | |
Sun et al. | Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma | |
Hao et al. | The significance of Siglec-15 expression in resectable non-small cell lung cancer. | |
Katono et al. | Clinicopathological significance of S100A10 expression in lung adenocarcinomas | |
Liu et al. | Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer | |
Zhao et al. | RETRACTED ARTICLE: MYO5A inhibition by miR-145 acts as a predictive marker of occult neck lymph node metastasis in human laryngeal squamous cell carcinoma | |
Zhou et al. | Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer | |
Asano et al. | Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma | |
Wong et al. | Abdominal monophasic synovial sarcoma is a morphological and immunohistochemical mimic of gastrointestinal stromal tumour | |
JP4782854B2 (ja) | 癌患者の潜在的転移能、予後、又は全生存を予測する方法 | |
Burmeister et al. | Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110322 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110707 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |